Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 534.5 DKK -1.35% Market Closed
Market Cap: 101B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Cash & Cash Equivalents Peer Comparison

Comparables:
ZEAL
ASND
B
BAVA
F
FLUO
BIOPOR

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Cash & Cash Equivalents
kr4.3B
CAGR 3-Years
-23%
CAGR 5-Years
49%
CAGR 10-Years
27%
Zealand Pharma A/S
CSE:ZEAL
Cash & Cash Equivalents
kr7.2B
CAGR 3-Years
93%
CAGR 5-Years
53%
CAGR 10-Years
37%
Ascendis Pharma A/S
NASDAQ:ASND
Cash & Cash Equivalents
€258.7m
CAGR 3-Years
-12%
CAGR 5-Years
-18%
CAGR 10-Years
36%
B
Bavarian Nordic A/S
CSE:BAVA
Cash & Cash Equivalents
kr816.4m
CAGR 3-Years
64%
CAGR 5-Years
48%
CAGR 10-Years
22%
F
Fluoguide AS
STO:FLUO
Cash & Cash Equivalents
kr21.7m
CAGR 3-Years
27%
CAGR 5-Years
226%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Cash & Cash Equivalents
kr103.9m
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
12%

See Also

What is Genmab A/S's Cash & Cash Equivalents?
Cash & Cash Equivalents
4.3B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Cash & Cash Equivalents amounts to 4.3B DKK.

What is Genmab A/S's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
27%

Over the last year, the Cash & Cash Equivalents growth was -60%. The average annual Cash & Cash Equivalents growth rates for Genmab A/S have been -23% over the past three years , 49% over the past five years , and 27% over the past ten years .

Back to Top